References
- Ray T . FDA stepping up actions against PGx testing, forcing some labs to stop reporting drug information. (2019). https://www.360dx.com/regulatory-news-fda-approvals/fda-stepping-actions-against-pgx-testing-forcing-some-labs-stop#.Xhx7BshKiUk
- USA Food and Drug Administration . Inova Genomics Laboratory FDA warning letter. (2019). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/inova-genomics-laboratory-577422-04042019
- USA Food and Drug Administration . The FDA warns against the use of many genetic tests with unapproved claims to predict patient response to specific medications: FDA safety communication. (2018). https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-use-many-genetic-tests-unapproved-claims-predict-patient-response-specific
- DailyMed. Escitalopram. (2020). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c871d3fe-5ca2-410c-976d-9ec4b72c878f
- DailyMed . Sertraline. (2020). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e6d920ee-80bc-4247-8b50-77f463130d38
- Hicks JK , BishopJR , SangkuhlKet al. Clinical Pharmacogenetics Implementation Consortium. Guideline for selective serotonin reuptake inhibitors and CYP2D6 and CYP2C19. Clin. Pharmacol. Ther.98(2), 127–134 (2015).
- Chang M , TybringG , DahlML , LindhJD. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clin. Pharmacokin.53(9), 801–811 (2014).
- Jukic MM , HaslemoT , MoldenE , Ingelman-SundbergM. Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients. Am. J. Psychiatry175(5), 463–470 (2018).
- Clinical Pharmacogenetics Implementation Consortium . Levels of evidence. (2019). https://cpicpgx.org/levels-of-evidence/
- DailyMed . Simvastatin. (2020). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cc2e27d-00d0-4398-9cc6-dafa63ea1ba1
- Ramsey LB , JohnsonSG , CaudleKEet al. Clinical Pharmacogenetics Implementation Consortium. Guideline for simvastatin and SLCO1B1. Supplemental information. Clin. Pharmacol. Ther.96(4), 423–428 (2014).
- Bottorff MB , BrightDR , KisorDF. Commentary: should pharmacogenomic evidence be considered in clinical decision-making? Focus on select cardiovascular drugs. Pharmacotherapy37(9), 1005–1013 (2017).
- USA Food and Drug Administration . Table of pharmacogenomic biomarkers in drug labeling. (2020). https://www.fda.gov/drugs/science-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
- Grandjean P . Paracelsus revisited: the dose concept in a complex world. Basic Clin. Pharmacol. Toxicol.119(2), 126–132 (2016).
- Huddart R , SangkuhlH , Whirl-CarrilloM , KleinTE. Are randomized controlled trials necessary to establish the value of implementing pharmacogenomics in the clinic?Clin. Pharmacol. Ther.106(2), 284–286 (2019).
- Gammal RS , CaudleKE , KleinTE , RellingMV. Considerations for pharmacogenomic testing in a health system. Genet. Med.21(8), 1886–1887 (2019).
- Frieden TR . Evidence for health decision making – beyond randomized, controlled trials. N. Engl. J. Med.377, 465–475 (2017).
- Wittich CM , BurkleCM , LanierWL. Ten common questions (and their answers) about off-label drug use. Mayo Clin. Proc.87(10), 982–990 (2012).
- The Clinical Pharmacogenetics Implementation Consortium (CPIC). (2020). https://cpicpgx.org/